Edition:
United States

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

1.34USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$1.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
52,574
52-wk High
$1.84
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Monday, 3 Oct 2016 08:30am EDT 

VIVUS Inc : VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales . VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra .VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.  Full Article

Vivus says extends return date of Stendra commercial rights
Monday, 29 Aug 2016 04:30pm EDT 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Vivus posts qtrly rev $13.8 mln vs $23.0 mln last year
Thursday, 4 Aug 2016 04:15pm EDT 

Vivus Inc : Qtrly loss per share $0.11 .Qtrly revenue $13.8 million versus $23.0 million.  Full Article

Vivus Inc says has files lawsuit -- 8-K
Wednesday, 27 Jul 2016 04:22pm EDT 

Vivus Inc : Says lawsuit was filed in response to an abbreviated new drug application filed by Hetero .Vivus Inc says has filed lawsuit in U.S. District court for district of New Jersey against Hetero USA, Inc. and Hetero Labs Limited.  Full Article

Vivus says to extend return date of Stendra commercial rights
Thursday, 30 Jun 2016 04:15pm EDT 

Vivus Inc : Vivus Inc says to extend return date of Stendra commercial rights .Extension of termination date of license agreement between Auxilium Pharmaceuticals and Vivus for Stendra â U.S. and Canadian commercial rights through August 31.  Full Article

Vivus files lawsuit against Teva for infringement of Qsymia Patents
Wednesday, 15 Apr 2015 07:30pm EDT 

Vivus Inc:Files a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd., collectively referred to as Teva.Lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Teva.VIVUS filed the lawsuit on the basis that Teva's proposed generic products infringe each of these patents held by VIVUS.  Full Article

VIVUS Inc appoints CFO - Form 8-K
Tuesday, 13 Jan 2015 04:06pm EST 

VIVUS Inc:Says on Jan. 7, 2015, it determined to remove the interim from Sanford’s title, such that Sanford’s title became chief financial officer and chief accounting officer effective Jan. 7, 2015.  Full Article

VIVUS Inc announces issuance of two additional U.S. Patents
Wednesday, 26 Nov 2014 07:00am EST 

VIVUS Inc:The United States Patent and Trademark Office has issued U.S. Patent Nos. 8,895,057 covering methods for effecting weight loss using Qsymia, and 8,895,058 covering compositions of Qsymia.  Full Article

BRIEF-Vivus reports Q3 net loss per share $0.09

* Qtrly total revenue $13.4 million versus $24.9 million Source text for Eikon: Further company coverage: